Terms: = Bone cancer AND KMT2A, TRX1, 4297, MLL, ENSG00000118058, MLL/GAS7, HTRX1, HRX, ALL-1, MLL1A, CXXC7 AND Prognosis
78 results:
1. A rare kmt2a::CBL transcript in an acute monoblastic leukemia patient with an unfavorable outcome.
Yu J; Song F; Zhang M; Xiao P; Feng J; Hong R; Hu Y; Huang H; Wei G
Mol Biol Rep; 2024 Apr; 51(1):561. PubMed ID: 38643442
[TBL] [Abstract] [Full Text] [Related]
2. Structural variants involving mllT10 fusion are associated with adverse outcomes in pediatric acute myeloid leukemia.
Abla O; Ries RE; Triche T; Gerbing RB; Hirsch B; Raimondi S; Cooper T; Farrar JE; Buteyn N; Harmon LM; Wen H; Deshpande AJ; Kolb EA; Gamis AS; Aplenc R; Alonzo T; Meshinchi S
Blood Adv; 2024 Apr; 8(8):2005-2017. PubMed ID: 38306602
[TBL] [Abstract] [Full Text] [Related]
3. Iron overload promotes the progression of mll-AF9 induced acute myeloid leukemia by upregulation of FOS.
Yang F; Cui X; Wang H; Zhang D; Luo S; Li Y; Dai Y; Yang D; Zhang X; Wang L; Zheng G; Zhang X
Cancer Lett; 2024 Feb; 583():216652. PubMed ID: 38242196
[TBL] [Abstract] [Full Text] [Related]
4. Integrated analysis of single-cell RNA-seq and bulk RNA-seq reveals RNA N6-methyladenosine modification associated with prognosis and drug resistance in acute myeloid leukemia.
Li Z; Liu X; Wang L; Zhao H; Wang S; Yu G; Wu D; Chu J; Han J
Front Immunol; 2023; 14():1281687. PubMed ID: 38022588
[TBL] [Abstract] [Full Text] [Related]
5. Clinical and Molecular Characteristics of Patients with Mixed Phenotype Acute Leukemia.
Kandeel EZ; Hassan NM; El Ashry MS
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1217-1223. PubMed ID: 37116143
[TBL] [Abstract] [Full Text] [Related]
6. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01.
Hosono N; Chi S; Yamauchi T; Fukushima K; Shibayama H; Katagiri S; Gotoh A; Eguchi M; Morishita T; Ogasawara R; Kondo T; Yanada M; Yamamoto K; Kobayashi T; Kuroda J; Usuki K; Utsu Y; Yoshimitsu M; Ishitsuka K; Ono T; Takahashi N; Iyama S; Kojima K; Nakamura Y; Fukuhara S; Izutsu K; Abutani H; Yamauchi N; Yuda J; Minami Y;
Cancer Sci; 2023 May; 114(5):2098-2108. PubMed ID: 36793248
[TBL] [Abstract] [Full Text] [Related]
7. DPY30 promotes the growth and survival of osteosarcoma cell by regulating the PI3K/AKT signal pathway.
Cheng G; An F; Cao Z; Zheng M; Zhao Z; Wu H
Eur J Histochem; 2023 Jan; 67(1):. PubMed ID: 36546421
[TBL] [Abstract] [Full Text] [Related]
8. Preclinical efficacy of azacitidine and venetoclax for infant kmt2a-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS
Leukemia; 2023 Jan; 37(1):61-71. PubMed ID: 36380143
[TBL] [Abstract] [Full Text] [Related]
9. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with kmt2a rearrangements.
Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J
BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338
[TBL] [Abstract] [Full Text] [Related]
10. Single-cell transcriptomics reveals a distinct developmental state of kmt2a-rearranged infant B-cell acute lymphoblastic leukemia.
Khabirova E; Jardine L; Coorens THH; Webb S; Treger TD; Engelbert J; Porter T; Prigmore E; Collord G; Piapi A; Teichmann SA; Inglott S; Williams O; Heidenreich O; Young MD; Straathof K; Bomken S; Bartram J; Haniffa M; Behjati S
Nat Med; 2022 Apr; 28(4):743-751. PubMed ID: 35288693
[TBL] [Abstract] [Full Text] [Related]
11. kmt2a-mllT1 and the Novel SEC16A-kmt2a in a Cryptic 3-Way Translocation t(9;11;19) Present in an Infant With Acute Lymphoblastic Leukemia.
de Matos RRC; Ferreira GM; Meyer C; Marschalek R; Larghero P; Ribeiro RC; Liehr T; Othman M; Bizarro MTSM; Sobral da Costa E; Land MGP; Abdelhay E; Binato R; Silva MLM
J Pediatr Hematol Oncol; 2022 Apr; 44(3):e719-e722. PubMed ID: 34966090
[TBL] [Abstract] [Full Text] [Related]
12. Minimal residual disease and outcome characteristics in infant kmt2a-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
Stutterheim J; de Lorenzo P; van der Sluis IM; Alten J; Ancliffe P; Attarbaschi A; Aversa L; Boer JM; Biondi A; Brethon B; Diaz P; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Leung AW; Locatelli F; Silverman L; Stary J; Szczepanski T; van der Velden VHJ; Vora A; Zuna J; Schrappe M; Valsecchi MG; Pieters R
Eur J Cancer; 2022 Jan; 160():72-79. PubMed ID: 34785111
[TBL] [Abstract] [Full Text] [Related]
13. Distinct clinico-biological features in AML patients with low allelic ratio FLT3-ITD: role of allogeneic stem cell transplantation in first remission.
Tien FM; Tsai CH; Huang SC; Liu JH; Chen CY; Kuo YY; Chuang YK; Tseng MH; Peng YL; Liu MC; Liu CW; Liao XW; Lin LI; Wu YS; Hou MF; Wu SJ; Hsu SC; Ko BS; Chou WC; Yao M; Hou HA; Tang JL; Tien HF
Bone Marrow Transplant; 2022 Jan; 57(1):95-105. PubMed ID: 34671120
[TBL] [Abstract] [Full Text] [Related]
14. Glycoproteome remodeling in mll-rearranged B-cell precursor acute lymphoblastic leukemia.
Oliveira T; Zhang M; Joo EJ; Abdel-Azim H; Chen CW; Yang L; Chou CH; Qin X; Chen J; Alagesan K; Almeida A; Jacob F; Packer NH; von Itzstein M; Heisterkamp N; Kolarich D
Theranostics; 2021; 11(19):9519-9537. PubMed ID: 34646384
[TBL] [Abstract] [Full Text] [Related]
15. The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.
Lafage-Pochitaloff M; Gerby B; Baccini V; Largeaud L; Fregona V; Prade N; Juvin PY; Jamrog L; Bories P; Hébrard S; Lagarde S; Mansat-De Mas V; Dovey OM; Yusa K; Vassiliou GS; Jansen JH; Tekath T; Rombaut D; Ameye G; Barin C; Bidet A; Boudjarane J; Collonge-Rame MA; Gervais C; Ittel A; Lefebvre C; Luquet I; Michaux L; Nadal N; Poirel HA; Radford-Weiss I; Ribourtout B; Richebourg S; Struski S; Terré C; Tigaud I; Penther D; Eclache V; Fontenay M; Broccardo C; Delabesse E
Blood Adv; 2022 Jan; 6(2):386-398. PubMed ID: 34638130
[TBL] [Abstract] [Full Text] [Related]
16. The ubiquitin ligase RNF5 determines acute myeloid leukemia growth and susceptibility to histone deacetylase inhibitors.
Khateb A; Deshpande A; Feng Y; Finlay D; Lee JS; Lazar I; Fabre B; Li Y; Fujita Y; Zhang T; Yin J; Pass I; Livneh I; Jeremias I; Burian C; Mason JR; Almog R; Horesh N; Ofran Y; Brown K; Vuori K; Jackson M; Ruppin E; Deshpande AJ; Ronai ZA
Nat Commun; 2021 Sep; 12(1):5397. PubMed ID: 34518534
[TBL] [Abstract] [Full Text] [Related]
17.
Zhang H; Wang X; Li S; Wang X; Lu X; Li M; Wang H; Liu Y; Pang H; Zhang L
Dis Markers; 2021; 2021():9932837. PubMed ID: 34194582
[TBL] [Abstract] [Full Text] [Related]
18. Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia.
Jaiswal AK; Truong H; Tran TM; Lin TL; Casero D; Alberti MO; Rao DS
Sci Rep; 2021 Jun; 11(1):13158. PubMed ID: 34162911
[TBL] [Abstract] [Full Text] [Related]
19. Novel Targeted Therapeutics in Acute Myeloid Leukemia: an Embarrassment of Riches.
Grieselhuber NR; Mims AS
Curr Hematol Malig Rep; 2021 Apr; 16(2):192-206. PubMed ID: 33738705
[TBL] [Abstract] [Full Text] [Related]
20. Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab.
Sutton R; Pozza LD; Khaw SL; Fraser C; Revesz T; Chamberlain J; Mitchell R; Trahair TN; Bateman CM; Venn NC; Law T; Ong E; Heatley SL; McClure BJ; Meyer C; Marschalek R; Henderson MJ; Cross S; White DL; Kotecha RS
Pediatr Blood Cancer; 2021 May; 68(5):e28922. PubMed ID: 33638292
[TBL] [Abstract] [Full Text] [Related]
[Next]
